(Boursier.com) — Drawing of an eleventh tranche of 300 bonds convertible into shares
Pharnext SA, a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative diseases currently without satisfactory therapeutic solution, proceeded to draw an eleventh tranche of 300 bonds convertible into shares with a nominal value of 10,000 euros each, and this under the contract for the issue of bond issues convertible or exchangeable into new and/or existing shares entered into with the company Global Tech Opportunities 13.
As for the funds received during the drawing of the previous tranches, the funds paid within the framework of this financing will be mainly used to finance the realization of the PREMIER trial, a pivotal clinical study of
Phase III of PXT3003, the company’s product candidate in Charcot-Marie-Tooth disease type 1A, and the open-label Phase III extension study.
The terms of this financing are described in the press release published on June 7, 2021, with regard to the terms amended by agreement between the Investor and the Company, in the press release dated
December 22, 2021 and in the 2021 financial results press release dated April 25, 2022. It is reminded that the OCEANE-BSA issuance program, from the second tranche, is implemented on the basis of the specific authorization voted by the shareholders of the Company during the Combined General Meeting of June 30, 2021 and the Extraordinary General Meeting of March 21, 2022 subject respectively to the twenty-third resolution and the first resolution.
©2022 Boursier.com